Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | BMC Cancer

Fig. 1

From: Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study

Fig. 1

Proportion of PSA-detected and symptomatic prostate cancer survivors# reporting moderate/severe* urinary, bowel and sexual problems, feeling depressed and lack of energy, measured using unadjusted individual items from the EPIC-26 questionnaire. Notes: See Additional file 1: Table S3 for further responses to individual questions, including confidence intervals and the results of statistical tests comparing patient groups. Error bars represent the 95% confidence intervals around each proportion. # Alive 18-42 months after diagnosis; * or equivalents such as poor/very poor

Back to article page